- Home
- ARWR vs BMRN Comparison
ARWR vs BMRN Comparison
Compare ARWR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | BMRN |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 11.4B |
| IPO Year | 2009 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ARWR | BMRN |
|---|---|---|
| Price | $85.30 | $64.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 18 |
| Target Price | $83.40 | ★ $88.22 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | $16,142,321.00 | ★ $1,313,646,000.00 |
| Revenue This Year | N/A | $15.02 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | ★ N/A | $84.79 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $22.73 | $49.26 |
| 52 Week High | $95.49 | $70.98 |
Technical Indicators
Market Signals| Indicator | ARWR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 50.46 |
| Support Level | $82.70 | $58.03 |
| Resistance Level | $87.83 | $66.28 |
| Average True Range (ATR) | 2.65 | 1.61 |
| MACD | -0.40 | -0.55 |
| Stochastic Oscillator | 26.08 | 3.17 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.